吸烟者和不吸烟者非小细胞肺癌的基因组图谱。
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
机构信息
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
出版信息
Cell. 2012 Sep 14;150(6):1121-34. doi: 10.1016/j.cell.2012.08.024.
Abstract
We report the results of whole-genome and transcriptome sequencing of tumor and adjacent normal tissue samples from 17 patients with non-small cell lung carcinoma (NSCLC). We identified 3,726 point mutations and more than 90 indels in the coding sequence, with an average mutation frequency more than 10-fold higher in smokers than in never-smokers. Novel alterations in genes involved in chromatin modification and DNA repair pathways were identified, along with DACH1, CFTR, RELN, ABCB5, and HGF. Deep digital sequencing revealed diverse clonality patterns in both never-smokers and smokers. All validated EFGR and KRAS mutations were present in the founder clones, suggesting possible roles in cancer initiation. Analysis revealed 14 fusions, including ROS1 and ALK, as well as novel metabolic enzymes. Cell-cycle and JAK-STAT pathways are significantly altered in lung cancer, along with perturbations in 54 genes that are potentially targetable with currently available drugs.
摘要
我们报告了 17 例非小细胞肺癌（NSCLC）患者肿瘤和相邻正常组织样本的全基因组和转录组测序结果。我们在编码序列中鉴定出 3726 个点突变和 90 多个插入缺失，吸烟者的突变频率比从不吸烟者高 10 多倍。鉴定出涉及染色质修饰和 DNA 修复途径的基因中的新改变，以及 DACH1、CFTR、RELN、ABCB5 和 HGF。深度数字测序揭示了从不吸烟者和吸烟者中不同的克隆性模式。所有经过验证的 EFGR 和 KRAS 突变都存在于创始克隆中，这表明它们可能在癌症起始中发挥作用。分析显示了 14 种融合，包括 ROS1 和 ALK，以及新型代谢酶。细胞周期和 JAK-STAT 途径在肺癌中发生显著改变，同时还存在 54 个可能用现有药物靶向治疗的潜在靶基因的扰动。
相似文献
1
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.吸烟者和不吸烟者非小细胞肺癌的基因组图谱。
Cell. 2012 Sep 14;150(6):1121-34. doi: 10.1016/j.cell.2012.08.024.
2
Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.中国女性不吸烟非腺癌非小细胞肺癌中驱动基因的表达谱分析。
Clin Lung Cancer. 2020 Sep;21(5):e355-e362. doi: 10.1016/j.cllc.2020.02.005. Epub 2020 Feb 10.
3
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.除烟草外因素：吸烟者和不吸烟者肺癌的基因组差异。
BMC Cancer. 2024 Aug 3;24(1):951. doi: 10.1186/s12885-024-12737-1.
4
Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.年轻从不吸烟者肺腺癌的基因组改变特征。
Int J Cancer. 2018 Oct 1;143(7):1696-1705. doi: 10.1002/ijc.31542. Epub 2018 May 7.
5
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.将下一代测序（NGS）纳入亚洲非小细胞肺癌（NSCLC）人群的实用性：可操作改变的增量收益和成本效益分析。
Lung Cancer. 2020 Jan;139:207-215. doi: 10.1016/j.lungcan.2019.11.022. Epub 2019 Nov 26.
6
The genomic landscape of nonsmall cell lung carcinoma in never smokers.从不吸烟者的非小细胞肺癌的基因组景观。
Int J Cancer. 2020 Jun 1;146(11):3207-3218. doi: 10.1002/ijc.32797. Epub 2019 Dec 10.
7
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.在常规检测中无 EGFR 和 ALK 改变的晚期非小细胞肺癌患者中，靶向 DNA 测序的获益。
Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21.
8
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.亚洲晚期非小细胞肺癌应用循环肿瘤 DNA 进行基因组分析的临床应用
Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.
9
A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers.女性从不吸烟者肺腺癌的高维、深度测序研究。
PLoS One. 2013;8(2):e55596. doi: 10.1371/journal.pone.0055596. Epub 2013 Feb 6.
10
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.非小细胞肺癌中分子改变的长尾：单机构在临床分子诊断中进行下一代测序的经验。
J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.
引用本文的文献
1
New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer.肺癌中ALK靶向治疗耐药的机制及治疗挑战的新进展
Cancer Drug Resist. 2025 Aug 25;8:43. doi: 10.20517/cdr.2025.122. eCollection 2025.
2
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.完善缺乏可靶向突变的非小细胞肺癌的治疗策略：多组学研究的见解
Br J Cancer. 2025 Aug 23. doi: 10.1038/s41416-025-03139-6.
3
Mapping the future: bibliometric analysis of omics research trends in non-small cell lung cancer.绘制未来蓝图：非小细胞肺癌组学研究趋势的文献计量分析
Discov Oncol. 2025 Aug 12;16(1):1536. doi: 10.1007/s12672-025-03140-8.
4
Tobacco smoke alters the trajectory of lung adenocarcinoma evolution via effects on somatic selection and epistasis.烟草烟雾通过对体细胞选择和上位性的影响改变肺腺癌的进化轨迹。
bioRxiv. 2025 Jul 25:2024.11.27.625765. doi: 10.1101/2024.11.27.625765.
5
Comorbidity of lung cancer and chronic obstructive pulmonary disease: correlation and optimization of treatment strategies.肺癌与慢性阻塞性肺疾病的共病：相关性及治疗策略的优化
Transl Lung Cancer Res. 2025 Jun 30;14(6):2296-2308. doi: 10.21037/tlcr-2025-480. Epub 2025 Jun 13.
6
Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling.清热活血方通过TREM2信号重塑肿瘤免疫微环境增强非小细胞肺癌的抗PD-1免疫治疗。
BMC Complement Med Ther. 2025 Jul 16;25(1):270. doi: 10.1186/s12906-025-05020-8.
7
Association between frailty and frailty change with chronic lung disease: results from two prospective cohort studies.衰弱与慢性肺病导致的衰弱变化之间的关联：两项前瞻性队列研究的结果
BMC Public Health. 2025 Jul 2;25(1):2283. doi: 10.1186/s12889-025-22601-x.
8
Evaluation of potential of targeted sequencing through mutational signature simulation.通过突变特征模拟评估靶向测序的潜力。
PLoS One. 2025 Jun 25;20(6):e0326071. doi: 10.1371/journal.pone.0326071. eCollection 2025.
9
Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.塑造战场：EGFR和KRAS肿瘤突变在肺癌免疫微环境及免疫治疗反应中的作用
Cancer Metastasis Rev. 2025 Jun 17;44(3):56. doi: 10.1007/s10555-025-10272-4.
10
Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.I型干扰素信号升高决定了ARF和p53突变肿瘤细胞的增殖优势。
Mol Cell Biol. 2025;45(6):246-261. doi: 10.1080/10985549.2025.2497817. Epub 2025 May 12.
本文引用的文献
1
MuSiC: identifying mutational significance in cancer genomes.MuSiC：识别癌症基因组中的突变意义。
Genome Res. 2012 Aug;22(8):1589-98. doi: 10.1101/gr.134635.111. Epub 2012 Jul 3.
2
BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data.BreakFusion：基于靶向组装的全转录组配对末端测序数据中基因融合的鉴定。
Bioinformatics. 2012 Jul 15;28(14):1923-4. doi: 10.1093/bioinformatics/bts272. Epub 2012 May 4.
3
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.多区域测序揭示的肿瘤内异质性和分支进化。
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
4
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks.RNA-seq 实验中使用 TopHat 和 Cufflinks 的差异基因和转录本表达分析。
Nat Protoc. 2012 Mar 1;7(3):562-78. doi: 10.1038/nprot.2012.016.
5
KIF5B-RET fusions in lung adenocarcinoma.肺腺癌中的 KIF5B-RET 融合。
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
6
RET, ROS1 and ALK fusions in lung cancer.肺癌中的 RET、ROS1 和 ALK 融合。
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
7
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.鉴定结直肠癌和肺癌活检组织中的新型 ALK 和 RET 基因融合。
Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.
8
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.对小儿髓母细胞瘤的基因组测序将灾难性的 DNA 重排与 TP53 突变联系起来。
Cell. 2012 Jan 20;148(1-2):59-71. doi: 10.1016/j.cell.2011.12.013.
9
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.早期 T 细胞前体急性淋巴细胞白血病的遗传基础。
Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.
10
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.全基因组测序揭示复发急性髓系白血病的克隆进化。
Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.
Zotero 插件